Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Baird Medical Investment Holdings (BDMD) Finished Goods (2023 - 2025)

Baird Medical Investment Holdings has reported Finished Goods over the past 3 years, most recently at $511000.0 for Q4 2025.

  • For Q4 2025, Finished Goods fell 28.76% year-over-year to $511000.0; the TTM value through Dec 2025 reached $511000.0, down 28.76%, while the annual FY2025 figure was $511000.0, 28.76% down from the prior year.
  • Finished Goods for Q4 2025 was $511000.0 at Baird Medical Investment Holdings, down from $717312.0 in the prior quarter.
  • Over five years, Finished Goods peaked at $717312.0 in Q4 2024 and troughed at $312871.0 in Q4 2023.
  • A 3-year average of $513727.7 and a median of $511000.0 in 2025 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: surged 129.27% in 2024 and later decreased 28.76% in 2025.
  • Year by year, Finished Goods stood at $312871.0 in 2023, then surged by 129.27% to $717312.0 in 2024, then fell by 28.76% to $511000.0 in 2025.
  • Business Quant data shows Finished Goods for BDMD at $511000.0 in Q4 2025, $717312.0 in Q4 2024, and $312871.0 in Q4 2023.